(Q37914882)

25 August 2017

1 reference

title

A review of palivizumab and emerging therapies for respiratory syncytial virus (English)

1 reference

25 August 2017

Kristin A Shadman

1

1 reference

25 August 2017

Ellen R Wald

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

11 August 2011

1 reference

Expert Opinion on Biological Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1455-1467

1 reference

Two distinct subtypes of human respiratory syncytial virus

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Demonstration of Respiratory Syncytial Virus in an Autopsy Series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Community study of role of viral infections in exacerbations of asthma in 9-11 year old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Antigenic and genetic diversity among the attachment proteins of group A respiratory syncytial viruses that have caused repeat infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

The burden of respiratory syncytial virus infection in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory syncytial virus infection in elderly and high-risk adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory viral infections in immunocompetent and immunocompromised persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Relationship of early childhood viral exposures to respiratory symptoms, onset of possible asthma and atopy in high risk children: the Canadian Asthma Primary Prevention Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Human metapneumovirus bronchiolitis in infancy is an important risk factor for asthma at age 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Rhinovirus illnesses during infancy predict subsequent childhood wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Severe viral respiratory infections in infants with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Immunisation in the current management of cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Down syndrome and respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Treatment of respiratory syncytial virus with palivizumab: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Management of RSV infections in adult recipients of hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

RNA interference therapy in lung transplant patients infected with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

Pharmacologic advances in the treatment and prevention of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

RSV604, a novel inhibitor of respiratory syncytial virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.608062

10.1517/14712598.2011.608062

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference